



Synonym

HLA-A*0201 & B2M & WT-1 (RMFPNAPYL)

Source

APC-Labeled Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein(HLW-HA2H6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & RMFPNAPYL peptide (Accession # [AAA59606.1](#) (HLA-A*02:01) & [P61769](#) (B2M) & RMFPNAPYL).
Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

APC-Labeled Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein is assembled by biotinylated monomer (HLW-H82E5) and APC-labeled streptavidin.

Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein is produced by co-expression of HLA and B2M loaded with WT-1 peptide. Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

Conjugate

APC
Excitation Wavelength: 640 nm
Emission Wavelength: 661 nm

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, 1% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 3 months under sterile conditions after reconstitution.

Background

Wilms tumor gene 1 (WT1), is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The WT1127-134 (RMFPNAPYL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1.

Clinical and Translational Updates

